Analysts and investors are unimpressed with the company's plans for a turnaround.
News & Analysis: Sequenom
Lowered guidance hits the genetic-test company.
Investors get spooked about a leadership change at the diagnostic test company.
UnitedHealthcare agrees to cover Sequenom's diagnostic tests.
Sequenom's shares got crushed today on the back of its second-quarter earnings report. Here's why.
Sequenom stock takes it on the chin in June following an unfavorable court ruling. Find out whether this is a buying opportunity, or all the more reason to keep your distance.
Sequenom decodes its way to big gains in December after settling a long-standing dispute with a larger rival. See what this could mean for investors over the long run.
Sequenom splices and dices its ways to huge gains after announcing the settlement of a long-standing patent dispute with a rival.
Is this meaningful or just another movement?
The stock market gave up ground Friday on fears of Russo-Ukrainian escalation, but these three stocks posted solid gains on good earnings results. Find out more about what made them soar.